OPINION: Tobacco Bill needs a clearer view of the science
Kenya's Tobacco Bill should distinguish between cigarettes, vapes, and nicotine pouches based on scientific evidence of their differing health risks.Summary
Dr. Michael Kariuki of the Harm Reduction Society of Kenya argues that Kenya's Tobacco Control (Amendment) Bill incorrectly treats all nicotine products as a single category, ignoring crucial scientific differences between cigarettes, vapes, and oral nicotine pouches. He emphasizes that the overwhelming burden of smoking-related disease comes from inhaling combustion byproducts, not nicotine itself. Citing a major UK government evidence review, he notes that vaping represents only a small fraction of the risks of smoking in the short and medium term. He also references a Cochrane living systematic review updated in August 2026 finding high-certainty evidence that nicotine vapes increase quit rates compared to conventional nicotine replacement therapy. In June, the US FDA authorized 20 nicotine pouch products to carry modified-risk claims, informing consumers that switching from cigarettes lowers the risk of several serious smoking-related diseases. Yale University research shows adults using flavoured nicotine products are twice as likely to quit cigarettes than those using tobacco flavours. While acknowledging legitimate concerns about youth access and marketing, Kariuki argues regulation should address these issues without depriving adults of potentially effective smoking cessation tools. The article concludes that Kenya's public health policy should recognise that none of these products are risk-free, but they are not equally harmful — combustion matters, relative risk matters, and the distinction between smoking and smoke-free alternatives matters scientifically.
(Source：Citizen Digital)
